161 related articles for article (PubMed ID: 17168727)
21. Nitric oxide synthase inhibitors enhance 5-HT2 receptor-mediated behavior, the head-twitch response in mice.
Kim HS; Son YR; Kim SH
Life Sci; 1999; 64(26):2463-70. PubMed ID: 10403505
[TBL] [Abstract][Full Text] [Related]
22. Aromatic reduced amide bond peptidomimetics as selective inhibitors of neuronal nitric oxide synthase.
Hah JM; Martásek P; Roman LJ; Silverman RB
J Med Chem; 2003 Apr; 46(9):1661-9. PubMed ID: 12699384
[TBL] [Abstract][Full Text] [Related]
23. Melatonin synthetic analogs as nitric oxide synthase inhibitors.
Camacho ME; Carrion MD; Lopez-Cara LC; Entrena A; Gallo MA; Espinosa A; Escames G; Acuna-Castroviejo D
Mini Rev Med Chem; 2012 Jun; 12(7):600-17. PubMed ID: 22512552
[TBL] [Abstract][Full Text] [Related]
24. Selective pharmacological inhibition of distinct nitric oxide synthase isoforms.
Southan GJ; Szabó C
Biochem Pharmacol; 1996 Feb; 51(4):383-94. PubMed ID: 8619882
[TBL] [Abstract][Full Text] [Related]
25. Progress in the development of selective nitric oxide synthase (NOS) inhibitors.
Salerno L; Sorrenti V; Di Giacomo C; Romeo G; Siracusa MA
Curr Pharm Des; 2002; 8(3):177-200. PubMed ID: 11812267
[TBL] [Abstract][Full Text] [Related]
26. Novel non-covalent thrombin inhibitors incorporating P(1) 4,5,6,7-tetrahydrobenzothiazole arginine side chain mimetics.
Marinko P; Krbavcic A; Mlinsek G; Solmajer T; Bakija AT; Stegnar M; Stojan J; Kikelj D
Eur J Med Chem; 2004 Mar; 39(3):257-65. PubMed ID: 15051174
[TBL] [Abstract][Full Text] [Related]
27. Structure and activity of NO synthase inhibitors specific to the L-arginine binding site.
Proskuryakov SY; Konoplyannikov AG; Skvortsov VG; Mandrugin AA; Fedoseev VM
Biochemistry (Mosc); 2005 Jan; 70(1):8-23. PubMed ID: 15701046
[TBL] [Abstract][Full Text] [Related]
28. Peptidomimetics - antagonists of the fibrinogen receptors: molecular design, structures, properties and therapeutic applications.
Andronati SA; Karaseva TL; Krysko AA
Curr Med Chem; 2004 May; 11(9):1183-211. PubMed ID: 15134514
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of endothelial cell amino acid transport System y+ by arginine analogs that inhibit nitric oxide synthase.
McDonald KK; Rouhani R; Handlogten ME; Block ER; Griffith OW; Allison RD; Kilberg MS
Biochim Biophys Acta; 1997 Feb; 1324(1):133-41. PubMed ID: 9059506
[TBL] [Abstract][Full Text] [Related]
30. Active site mapping of trypsin, thrombin and matriptase-2 by sulfamoyl benzamidines.
Dosa S; Stirnberg M; Lülsdorff V; Häußler D; Maurer E; Gütschow M
Bioorg Med Chem; 2012 Nov; 20(21):6489-505. PubMed ID: 23026080
[TBL] [Abstract][Full Text] [Related]
31. Nitric oxide synthase inhibitors and cerebral vasospasm.
Jung CS
Acta Neurochir Suppl; 2011; 110(Pt 1):87-91. PubMed ID: 21116921
[TBL] [Abstract][Full Text] [Related]
32. Is the bound substrate in nitric oxide synthase protonated or neutral and what is the active oxidant that performs substrate hydroxylation?
de Visser SP; Tan LS
J Am Chem Soc; 2008 Oct; 130(39):12961-74. PubMed ID: 18774806
[TBL] [Abstract][Full Text] [Related]
33. Mechanism-based isocoumarin inhibitors for serine proteases: use of active site structure and substrate specificity in inhibitor design.
Powers JC; Kam CM; Narasimhan L; Oleksyszyn J; Hernandez MA; Ueda T
J Cell Biochem; 1989 Jan; 39(1):33-46. PubMed ID: 2654146
[TBL] [Abstract][Full Text] [Related]
34. Normal circulating adult human red blood cells contain inactive NOS proteins.
Kang ES; Ford K; Grokulsky G; Wang YB; Chiang TM; Acchiardo SR
J Lab Clin Med; 2000 Jun; 135(6):444-51. PubMed ID: 10850643
[TBL] [Abstract][Full Text] [Related]
35. Design and structure of peptide and peptidomimetic antagonists of protein-protein interaction.
Sillerud LO; Larson RS
Curr Protein Pept Sci; 2005 Apr; 6(2):151-69. PubMed ID: 15853652
[TBL] [Abstract][Full Text] [Related]
36. Structural requirements for inhibition of the neuronal nitric oxide synthase (NOS-I): 3D-QSAR analysis of 4-oxo- and 4-amino-pteridine-based inhibitors.
Matter H; Kotsonis P; Klingler O; Strobel H; Fröhlich LG; Frey A; Pfleiderer W; Schmidt HH
J Med Chem; 2002 Jul; 45(14):2923-41. PubMed ID: 12086480
[TBL] [Abstract][Full Text] [Related]
37. Inhibitor Bound Crystal Structures of Bacterial Nitric Oxide Synthase.
Holden JK; Dejam D; Lewis MC; Huang H; Kang S; Jing Q; Xue F; Silverman RB; Poulos TL
Biochemistry; 2015 Jul; 54(26):4075-82. PubMed ID: 26062720
[TBL] [Abstract][Full Text] [Related]
38. Design and synthesis of C5 methylated L-arginine analogues as active site probes for nitric oxide synthase.
Martin NI; Woodward JJ; Winter MB; Beeson WT; Marletta MA
J Am Chem Soc; 2007 Oct; 129(41):12563-70. PubMed ID: 17892291
[TBL] [Abstract][Full Text] [Related]
39. Subcellular Targeting of Nitric Oxide Synthases Mediated by Their N-Terminal Motifs.
Costas-Insua C; Merino-Gracia J; Aicart-Ramos C; Rodríguez-Crespo I
Adv Protein Chem Struct Biol; 2018; 111():165-195. PubMed ID: 29459031
[TBL] [Abstract][Full Text] [Related]
40. Discovery of a novel, potent, and specific family of factor Xa inhibitors via combinatorial chemistry.
Ostrem JA; al-Obeidi F; Safar P; Safarova A; Stringer SK; Patek M; Cross MT; Spoonamore J; LoCascio JC; Kasireddy P; Thorpe DS; Sepetov N; Lebl M; Wildgoose P; Strop P
Biochemistry; 1998 Jan; 37(4):1053-9. PubMed ID: 9454596
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
